Antithrombogenic surface

• US 5,342,621 A
• Filed: 09/15/1992
• Issued: 08/30/1994
• Est. Priority Date: 09/15/1992
• Status: Expired due to Term

• Current Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Advanced Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Eury, Robert P.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Kulkosky, Peter F.
• Application Number:
  US07/945,107
• Time in Patent Office: 714 Days
• Field of Search: 424/486, 424/450, 424/426, 424/428, 424/488, 424/423, 604/265
• US Class Current: 424/423
• CPC Class Codes: A61L 33/0011 Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
• CPC Class Codes: A61L 33/0029 using an intermediate layer of polymer
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

An anticoagulant releasably associated with a cell membrane mimicking substance is incorporated in a biomedical polymer or polymer coating and serves to both prevent the blood from recognizing the polymer as a foreign substance as well as actively interfere in any coagulation process that may occur.

Claims

1. An antithrombogenic material comprising:

heparin, an anticoagulation agent, complexed with phosphatidylcholine, a cell membrane mimicking substance, so as to be releasably associated therewith, incorporated within a biomedical polymer.

2. A biomedical device formed of the antithrombogenic material of claim 1.

3. A biomedical device coated with the antithrombogenic material of claim 1.

4. A stent coated with antithrombogenic material of claim 1.

5. The antithrombogenic material of claim 1 wherein said biomedical polymer is selected from the group consisting of polyurethanes, polyamides, polycarbonates, and polyesters.

6. The antithrombogenic material of claim 1 wherein said biomedical polymer comprises a biodegradable polymer and wherein said material is applied as a film to blood contacting surfaces of a medical device.

7. The antithrombogenic material of claim 6 wherein said biodegradable polymer comprises poly-L-lactic acid (PLLA)

8. A method for imparting antithrombogenic characteristics to a medical device, comprising the steps of:

forming a solution which supports heparin, an anticoagulation agent, complexed with phosphatidylcholine, a cell membrane mimicking substance, so as to be releasably associated therewith;

coating preselected surfaces of said medical device with said solution; and

drying said coating to provide a dry film adhering to said surfaces.

9. The method of claim 8 wherein said solution includes a heparin-phosphatidylcholine complex and poly-L-lactic acid polymer.

10. The method of claim 8 wherein said medical device comprises a stent.

11. A method for imparting antithrombogenic characteristics to a medical device, comprising the steps of:

forming a dry film containing heparin, an anticoagulation agent, complexed with phosphatidylcholine, a cell mimicking substance, so as to be releasably associated therewith;

placing said dry film on selected surfaces of said medical device;

heating said dry film to soften and adhere said film to said surfaces.

12. The method of claim 16 wherein said film further contains a biodegradable polymer.

13. The method of claim 12 wherein said polymer comprises poly-L-lactic acid.

14. A method for producing a medical device having antithrombogenic characteristics, comprising the steps of:

forming a substance having heparin, an anticoagulation agent complexed with phosphatidylcholine, a cell mimicking compound so as to be releasably associated therewith;

intimately admixing said substance with a structural polymer; and

forming said medical device with said admixture.